At a glance
ClinicalIndex Comparison RecordPhase 1Suspended· 15 target
Drug / intervention
autologous adipose derived mesenchymal stem cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Cerebral Palsy
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Aug 24, 2021·Updated Apr 17, 2025
In Brief
A Phase 1 clinical trial evaluating autologous adipose derived mesenchymal stem cells for Cerebral Palsy. Suspended, targeting 15 participants across 1 site.
Signals
Trial is currently suspended
Detailed Summary
This trial will study the safety and efficacy of intravenous infusion of cultured autologous adult adipose derived mesenchymal stem cells for the treatment of Cerebral Palsy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebral Palsy
CountriesGreece
Collaborators--
Timeline
Phase 1Suspended
20222023202420252026202720282029
First PostedAug 2021
Enrollment StartDec 2025
TodayJul 2026
Primary CompletionDec 2028
First PostedAug 24, 2021
Enrollment StartDec 1, 2025
Primary CompletionDec 1, 2028
TodayJul 1, 2026
Enrollment to primary: 3 yearsPosted 4.9 years agoPrimary completion in 2.4 years
Interventions
autologous adipose derived mesenchymal stem cellsbiological
cultured autologous adult adipose derived mesenchymal stem cells